MX2020008445A - Metodos para tratar el cancer con anticuerpos anti-pd-1. - Google Patents

Metodos para tratar el cancer con anticuerpos anti-pd-1.

Info

Publication number
MX2020008445A
MX2020008445A MX2020008445A MX2020008445A MX2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A
Authority
MX
Mexico
Prior art keywords
antigen
methods
binding fragment
treating cancer
antibodies
Prior art date
Application number
MX2020008445A
Other languages
English (en)
Spanish (es)
Inventor
Mallika Lala
Lokesh Jain
Mengyao Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67620026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020008445(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020008445A publication Critical patent/MX2020008445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2020008445A 2018-02-13 2019-02-08 Metodos para tratar el cancer con anticuerpos anti-pd-1. MX2020008445A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18
PCT/US2019/017177 WO2019160751A2 (en) 2018-02-13 2019-02-08 Methods for treating cancer with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
MX2020008445A true MX2020008445A (es) 2020-09-28

Family

ID=67620026

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008445A MX2020008445A (es) 2018-02-13 2019-02-08 Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2024013016A MX2024013016A (es) 2018-02-13 2020-08-12 Anticuerpos anti-pd1 para usarse en el tratamiento del cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013016A MX2024013016A (es) 2018-02-13 2020-08-12 Anticuerpos anti-pd1 para usarse en el tratamiento del cancer

Country Status (14)

Country Link
US (2) US12358984B2 (enExample)
EP (1) EP3752180A4 (enExample)
JP (2) JP2021513541A (enExample)
KR (1) KR20200119844A (enExample)
CN (2) CN111712255A (enExample)
AU (2) AU2019220495B2 (enExample)
BR (1) BR112020016331A8 (enExample)
CA (1) CA3090995A1 (enExample)
CL (1) CL2020002075A1 (enExample)
IL (1) IL276303A (enExample)
MA (1) MA52789A (enExample)
MX (2) MX2020008445A (enExample)
SG (1) SG11202007590TA (enExample)
WO (1) WO2019160751A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
US20220380469A1 (en) * 2019-09-27 2022-12-01 Merck Sharp & Dohme Corp. Methods for treating metastatic triple negative breast cancer with anti-pd-1 antibodies
SI4076385T1 (sl) 2019-12-20 2026-04-30 Formycon Ag Formulacije protiteles anti-pd1
US20230050449A1 (en) * 2019-12-20 2023-02-16 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备
CN112394102B (zh) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用
JP2024527517A (ja) 2021-06-23 2024-07-25 フォーマイコン アーゲー 抗ｐｄ１抗体製剤
US20250011453A1 (en) * 2021-07-20 2025-01-09 Merck Sharp & Dohme Llc Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
CN113893343A (zh) * 2021-10-16 2022-01-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗宫颈癌患者的药物中的用途
US20250044295A1 (en) * 2021-12-16 2025-02-06 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy
EP4637818A1 (en) 2022-12-21 2025-10-29 Formycon AG Formulations of anti-pd1 antibodies
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20230030022A (ko) 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
CN108883132A (zh) 2016-01-22 2018-11-23 X4 制药有限公司 用于治疗癌症的方法
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
TWI910495B (zh) 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
EP3463453A1 (en) 2016-05-23 2019-04-10 Eli Lilly and Company Combination of pembrolizumab and abemaciclib for the treatment of cancer
CN109476753A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗肿瘤的方法的抗-pd-1抗体
MY192158A (en) 2016-09-14 2022-08-03 Abbvie Biotherapeutics Inc Anti-pd-1 antibodies and their uses
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
KR20240149982A (ko) * 2017-06-01 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Also Published As

Publication number Publication date
BR112020016331A2 (pt) 2020-12-15
CN120919306A (zh) 2025-11-11
WO2019160751A2 (en) 2019-08-22
JP2021513541A (ja) 2021-05-27
CN111712255A (zh) 2020-09-25
EP3752180A2 (en) 2020-12-23
CL2020002075A1 (es) 2020-10-23
AU2026201041A1 (en) 2026-03-05
US12358984B2 (en) 2025-07-15
BR112020016331A8 (pt) 2023-02-07
RU2020129827A (ru) 2022-03-14
MA52789A (fr) 2021-04-14
MX2024013016A (es) 2024-11-08
IL276303A (en) 2020-09-30
EP3752180A4 (en) 2021-12-15
JP2024038251A (ja) 2024-03-19
US20240026003A1 (en) 2024-01-25
AU2019220495A1 (en) 2020-08-13
US20210047408A1 (en) 2021-02-18
WO2019160751A3 (en) 2020-09-10
CA3090995A1 (en) 2019-08-22
KR20200119844A (ko) 2020-10-20
AU2019220495B2 (en) 2025-11-13
SG11202007590TA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
CO2017011536A2 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2020010913A (es) Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
MX2023015070A (es) Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo.
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
AR130745A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
MX2022000332A (es) Anticuerpos contra el receptor de muerte celular programada pd-1 humano.
MX2022006883A (es) Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario.